Literature DB >> 19346379

Relapse of visceral leishmaniasis after miltefosine treatment in a Nepalese patient.

Basu Dev Pandey1, Kishor Pandey, Osamu Kaneko, Tetsuo Yanagi, Kenji Hirayama.   

Abstract

We report the first case of visceral leishmaniasis (VL) relapse in a healthy individual after complete miltefosine treatment. The patient attended hospital with a history of fever for 2 months, splenomegaly, hepatomegaly, and weight loss. The case was confirmed as VL by microscopical detection of Leishmania parasites in a bone marrow specimen and by a positive result for the immunochromatography-based test targeting the Leishmania donovani rK39 antibody. A polymerase chain reaction (PCR) specific for the Leishmania kinetoplast minicircle gene was positive, and subsequent sequencing of the PCR-amplified product confirmed that this case was a L. donovani infection. The patient was treated with miltefosine for 28 days, during which time the response was good, and the Leishman-Donovan body (LD body) was negative on discharge. Ten months later, however, this patient again developed high fever and splenomegaly, and LD bodies and rK39 antibody were positive, thus indicating a relapse of VL. The patient was subsequently treated with 1 mg/kg of amphotericin B for a total of 14 days and recovered completely.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19346379

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  29 in total

1.  Case report: Expansion of visceral leishmaniasis to the western hilly part of Nepal.

Authors:  Basu Dev Pandey; Sher Bahadur Pun; Osamu Kaneko; Kishor Pandey; Kenji Hirayama
Journal:  Am J Trop Med Hyg       Date:  2011-01       Impact factor: 2.345

2.  Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.

Authors:  Arpita Kulshrestha; Vasundhra Bhandari; Rupkatha Mukhopadhyay; V Ramesh; Shyam Sundar; Louis Maes; Jean Claude Dujardin; Syamal Roy; Poonam Salotra
Journal:  Parasitol Res       Date:  2012-12-13       Impact factor: 2.289

3.  Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant Leishmania donovani.

Authors:  Arpita Kulshrestha; Vanila Sharma; Ruchi Singh; Poonam Salotra
Journal:  Parasitol Res       Date:  2014-01-22       Impact factor: 2.289

4.  Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.

Authors:  Nishi Shakya; Preeti Bajpai; Suman Gupta
Journal:  J Parasit Dis       Date:  2011-05-20

5.  Visceral leishmaniasis from a non-endemic Himalayan region of Nepal.

Authors:  Mitesh Shrestha; Basu Dev Pandey; Jyoti Maharjan; Shyam Prakash Dumre; Prakash Nidhi Tiwari; Krishna Das Manandhar; Sher Bahadur Pun; Kishor Pandey
Journal:  Parasitol Res       Date:  2018-05-02       Impact factor: 2.289

6.  Ammonium trichloro [1,2-ethanediolato-O,O']-tellurate cures experimental visceral leishmaniasis by redox modulation of Leishmania donovani trypanothione reductase and inhibiting host integrin linked PI3K/Akt pathway.

Authors:  Preeti Vishwakarma; Naveen Parmar; Pragya Chandrakar; Tanuj Sharma; Manoj Kathuria; Pramod K Agnihotri; Mohammad Imran Siddiqi; Kalyan Mitra; Susanta Kar
Journal:  Cell Mol Life Sci       Date:  2017-09-12       Impact factor: 9.261

7.  Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern.

Authors:  Jyotsna Mishra; Rentala Madhubala; Sarman Singh
Journal:  Parasitol Res       Date:  2012-12-18       Impact factor: 2.289

8.  Ketanserin, an antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani.

Authors:  Sushma Singh; Neeradi Dinesh; Preet Kamal Kaur; Baigadda Shamiulla
Journal:  Parasitol Res       Date:  2014-04-12       Impact factor: 2.289

9.  Successful Therapy of Murine Visceral Leishmaniasis with Astrakurkurone, a Triterpene Isolated from the Mushroom Astraeus hygrometricus, Involves the Induction of Protective Cell-Mediated Immunity and TLR9.

Authors:  Suvadip Mallick; Aritri Dutta; Ankur Chaudhuri; Debasri Mukherjee; Somaditya Dey; Subhadra Halder; Joydip Ghosh; Debarati Mukherjee; Sirin Salma Sultana; Gunjan Biswas; Tapan Kumar Lai; Pradyumna Patra; Indranil Sarkar; Sibani Chakraborty; Bhaskar Saha; Krishnendu Acharya; Chiranjib Pal
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 10.  Drug resistance in visceral leishmaniasis.

Authors:  Helena C Maltezou
Journal:  J Biomed Biotechnol       Date:  2009-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.